

GPI

Sector: Industrials

OUTPERFORM

Price: Eu10.32 - Target: Eu14.00

New BP Shows Sustained Growth

Gianluca Bertuzzo +39-02-77115.429

gianluca.bertuzzo@intermonte.it

Andrea Randone: +39-02-77115.364

andrea.randone@intermonte.it


Stock Rating

Rating: Unchanged

Target Price (Eu): from 13.70 to 14.00

	2024E	2025E	2026E
Chg in Adj EPS	0.0%	1.5%	5.0%

GPI - 12M Performance



Stock Data

Reuters code: GPI.MI

Bloomberg code: GPI IM

Performance	1M	3M	12M
Absolute	2.0%	-16.4%	13.3%
Relative	-4.6%	-19.0%	-5.2%
12M (H/L)	13.30/8.96		
3M Average Volume (th):	21.82		

Shareholder Data

No. of Ord shares (mn): 29

Total no. of shares (mn): 29

Mkt Cap Ord (Eu mn): 298

Total Mkt Cap (Eu mn): 298

Mkt Float - Ord (Eu mn): 102

Mkt Float (in %): 34.0%

Main Shareholder:

FM Srl (F. Manzana, CEO) 47.6%

Balance Sheet Data

Book Value (Eu mn): 300

BVPS (Eu): 10.42

P/BV: 1.0

Net Financial Position (Eu mn): -341

Enterprise Value (Eu mn): 638

GPI unveiled its new, 2025-29 BP which lays the foundation for the post-pandemic evolution. Key pillars are coherent and consistent with expectations, with GPI aiming to capitalize on its leadership in *Software* in Italy, grow abroad through already successful vertical software, increase efficiency by consolidating the product offering and optimizing the corporate structure, and favouring higher profit projects in *Care* and *Automation*. As for financial targets, the BP implies sustained, entirely organic and stronger-than-expected growth for which we conservatively leave some upside. Without large M&A deals envisaged, leverage is seen improving, underpinning some FCF generation. All in all, the BP supports our investment case with the company set to benefit from investments in healthcare digitalisation, which enables better, cost-efficient services thanks to its market position and broad product range. TP to €14.0, +2%, on slightly higher estimates.

■ **Post-pandemic evolution lays foundation for new BP.** In order to appreciate the new BP, an understanding of GPI's key achievements over the 2020-24 period is crucial: i) it became the 1st player in the Italian healthcare software market, capitalizing on its consolidation strategy and the shift by the PA towards a centralized purchasing model (*Software* unit achieved a 16% organic CAGR); ii) expanded abroad (from 9% to 22%) and into new software verticals through M&A; iii) rationalized its *non-software* activities (from 32% of EBITDA to 10%), through M&A (sale of Pay) and lower growth vs *Software*.

■ **2025-29 plan: extracting value.** The BP is based on four key pillars:

- Consolidate national leadership through growth of the Core Offering (HIS, Social Care, ERP, Data Analytics and HR) with AI enhancing existing products. Telemedicine growth will be pursued, although results will depend on evolution of the organizational model of the public health system. Importantly, growth is expected to continue, with the end of NRRP financing not expected to create a vacuum;
- Develop an international presence focusing on vertical software apps that have already proven their success and have growth leeway (Blood, Diagnostics and Critical Care);
- Transform the organization in order to increase efficiency. Actions concern the integration and consolidation of the product offering to foster commercial and industrial synergies, and merging redundant corporate functions scattered across the organization (resulting from the M&A spree) in order to optimize the cost base;
- Capture value from non-software activities. For *Care*, recovery of profitability (burdened by labour cost inflation not covered by base contracts) through a focus on the most profitable projects and continuous technology implementation. For *Automation*, international expansion and innovation will be key.

■ **Financial targets: organic, profitable growth with a greater focus on value creation.** 2027/29 targets are: revenues >€6/700mn, a 6/7% entirely organic CAGR on 2024E numbers, with large M&A deals not envisaged; EBITDA >€132/175mn with >22/25% margin and 9/11% CAGR; net debt/EBITDA <2.7/2.5x after a yearly DPS of ~€0.7, implying 2027 net debt <€356mn on cumulative ~€40mn FCF. Interestingly, ROIC (EBIT/NIC) targets were set at >11/15%, signalling a greater focus on value creation. Overall, P&L targets show some upside (HSD) also compared to our new, slightly improved, forecast.

Key Figures & Ratios	2022A	2023A	2024E	2025E	2026E
Sales (Eu mn)	347	433	503	531	554
EBITDA Adj (Eu mn)	49	80	102	111	118
Net Profit Adj (Eu mn)	6	7	14	16	25
EPS New Adj (Eu)	0.199	0.234	0.488	0.585	0.901
EPS Old Adj (Eu)	0.199	0.234	0.488	0.576	0.858
DPS (Eu)	0.500	0.850	0.700	0.700	0.700
EV/EBITDA Adj	11.0	8.5	6.6	5.7	5.4
EV/EBIT Adj	26.1	24.5	18.6	13.3	11.2
P/E Adj	51.9	44.0	21.2	17.6	11.4
Div. Yield	4.8%	8.2%	6.8%	6.8%	6.8%
Net Debt/EBITDA Adj	2.9	4.5	3.3	3.1	2.9

DISCLAIMER (for more details go to [DISCLAIMER](#))

IMPORTANT DISCLOSURES

The reproduction of the information, recommendations and research produced by Intermonte SIM contained herein and of any its parts is strictly prohibited. None of the contents of this document may be shared with third parties without authorisation from Intermonte.

This report is directed exclusively at market professional and other institutional investors (Institutions) and is not for distribution to person other than "Institution" ("Non-Institution"), who should not rely on this material. Moreover, any investment or service to which this report may relate will not be made available to Non-Institution.

The information and data in this report have been obtained from sources which we believe to be reliable, although the accuracy of these cannot be guaranteed by Intermonte. In the event that there be any doubt as to their reliability, this will be clearly indicated. The main purpose of the report is to offer up-to-date and accurate information in accordance with regulations in force covering "recommendations" and is not intended nor should it be construed as a solicitation to buy or sell securities.

This disclaimer is constantly updated on Intermonte's website www.intermonte.it under LEGAL INFORMATION. Valuations and recommendations can be found in the text of the most recent research and/or reports on the companies in question. For a list of all recommendations made by Intermonte on any financial instrument or issuer in the last twelve months consult the [PERFORMANCE](#) web page.

Intermonte distributes research and engages in other approved activities with respect to Major U.S. Institutional Investors ("Majors") and other Qualified Institutional Buyers ("QIBs"), in the United States, via Plural Securities LLC under SEC 15a-6 guidelines. Intermonte is not registered as a broker dealer in the United States under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and is not a member of the Securities Investor Protection Corporation ("SIPC"). Plural Securities LLC is registered as a broker-dealer under the Exchange Act and is a member of SIPC.

ANALYST CERTIFICATION

For each company mentioned in this report the respective research analyst hereby certifies that all of the views expressed in this research report accurately reflect the analyst's personal views about any or all of the subject issuer (s) or securities. The analyst (s) also certifies that no part of their compensation was, is or will be directly or indirectly related to the specific recommendation or view in this report.

The analyst (s) responsible for preparing this research report receive(s) compensation that is based upon various factors, including Intermonte's total profits, a portion of which is generated by Intermonte's corporate finance activities, although this is minimal in comparison to that generated by brokerage activities.

Intermonte's internal procedures and codes of conduct are aimed to ensure the impartiality of its financial analysts. The exchange of information between the Corporate Finance sector and the Research Department is prohibited, as is the exchange of information between the latter and the proprietary equity desk in order to prevent conflicts of interest when recommendations are made.

The analyst responsible for the report is not a) a resident of US; b) an associated person of a U.S. broker-dealer; c) supervised by a supervisory principal of a U.S. broker-dealer. This Research Report is distributed in the U.S. through Plural Securities LLC, 950 3rd Ave, Suite 1702, NY 10022, USA.

GUIDE TO FUNDAMENTAL RESEARCH

The main methods used to evaluate financial instruments and set a target price for 12 months after the investment recommendation are as follows:

- Discounted cash flow (DCF) model or similar methods such as a dividend discount model (DDM)
- Comparison with market peers, using the most appropriate methods for the individual company analysed: among the main ratios used for industrial sectors are price/ earnings (P/E), EV/EBITDA, EV/EBIT, price /sales.
- Return on capital and multiples of adjusted net book value are the main methods used for banking sector stocks, while for insurance sector stocks return on allocated capital and multiples on net book value and embedded portfolio value are used
- For the utilities sector comparisons are made between expected returns and the return on the regulatory asset base (RAB)

Some of the parameters used in evaluations, such as the risk-free rate and risk premium, are the same for all companies covered, and are updated to reflect market conditions. Currently a risk-free rate of 4.0% and a risk premium of 5.5% are being used.

Frequency of research: quarterly.

Reports on all companies listed on the S&P500 Index, most of those on the MIBEX Index and the main small caps (regular coverage) are published at least once per quarter to comment on results and important newsflow.

A draft copy of each report may be sent to the subject company for its information (without target price and/or recommendations), but unless expressly stated in the text of the report, no changes are made before it is published.

Explanation of our ratings system:

- BUY: stock expected to outperform the market by over 25% over a 12 month period;
- OUTPERFORM: stock expected to outperform the market by between 10% and 25% over a 12 month period;
- NEUTRAL: stock performance expected at between +10% and -10% compared to the market over a 12 month period;
- UNDERPERFORM: stock expected to underperform the market by between -10% and -25% over a 12 month period;
- SELL: stock expected to underperform the market by over 25% over a 12 month period.

Prices: The prices reported in the research refer to the price at the close of the previous day of trading

CURRENT INVESTMENT RESEARCH RATING DISTRIBUTIONS

Intermonte SIM is authorised by CONSOB to provide investment services and is listed at n° 246 in the register of brokerage firms.

As at 31 December 2024 Intermonte's Research Department covered 132 companies. Intermonte's distribution of stock ratings is as follows:

BUY:	31.34 %
OUTPERFORM:	43.28 %
NEUTRAL:	25.38 %
UNDERPERFORM	00.00 %
SELL:	00.00 %

The distribution of stock ratings for companies which have received corporate finance services from Intermonte in the last 12 months (71 in total) is as follows:

BUY:	50.70 %
OUTPERFORM:	29.58 %
NEUTRAL:	19.72 %
UNDERPERFORM	00.00 %
SELL:	00.00 %

CONFLICT OF INTEREST

In order to disclose its possible conflicts of interest Intermonte SIM states that:

Intermonte is acting as financial advisor to Retex S.p.A. – Società Benefit in relation to the voluntary public tender offer launched on Alkemy S.p.A.

Intermonte SIM has provided in the last 12 months / provides / may provide investment banking services to the following companies: Aquafil, Banca Ifis, Civitanavi Systems, Cy4Gate, Esprinet, GPI, Eagle (on Greenthesis shares), Growens, Illimity Bank, Maire Tecnimont, SAES Getters, Tinexta, Unidata and WIT.

Intermonte SIM is acting as counterparty to WIT Fin S.r.l. in connection with call and put options having WIT S.p.A. shares and dividends as reference underlying.

Intermonte SIM is Specialist and/or Corporate Broker and/or Sponsor and/or Broker in charge of the share buy back activity of the following companies: Abitare In, Alkemy, Anima Holding, Antares Vision, Aquafil, Avio, Banca Ifis, Banca Sistema, Civitanavi Systems, Cyberoo, Cy4gate, DHH, El.En, Elica, Emak, Esprinet, Fimit - Fondo Alpha, Fine Foods, Franchi Umberto Marmi, GPI, Greenthesis (formerly Amblienthesis), IEG, IndelB, Intred, Luve, Mistano & Stracuzzi, Mondadori, Notorious Pictures, Omer, Pharmanutra, Relatech, Reply, Revo Insurance, Reway, Saes Getters, Sciuiker Frames, Servizi Italia, Sesa, Seri Industrial, Somec, Star7, Sy5-Dat Group, Talea, Tamburi, Tinexta, Tesmec, The Italian Sea Group, TXT, Unidata, Webuild and WIT.

Intermonte SIM has a contractual commitment to act as liquidity provider on behalf of third parties for the following company: Banca Sistema.

Intermonte SIM performs as a market maker for the following companies: A2A, Anima, Atlantia, Autogrill, Azimut Holding, BAMI, Banca Generali, Banca Mediolanum, Brembo, Buzzi, CNHI, Enel, ENI, Exor, Fineco, FCA, FTMIB, Generali, Italgas, Iren, Intesa Sanpaolo, Leonardo, Mediobanca, Moncler, Mediaset, Pirelli&C, Prysmian, Poste, Ferrari, Saipem, Snam, STM, Tenaris, Telecom Italia, Telecom Italia sav, Terna, UBI, Unicredit, Unipol, UnipolSai.

Intermonte SIM, through Websim, which constitute the digital division of Intermonte, acts as a Financial Content Provider and/or Specialist and/or Corporate Broker on the following companies: Abitare In, Alkemy, Allcore, Almawave, Banca Sistema, Bifire S.P.A., B&C Speakers, Casta Diva Group, Cleanbnb, Coffe, Crowdfundme, Cube Labs, Cy4gate, Cyberoo, DHH, Digital Bros, Digital Magics, Digitouch, Doxee, Edilziacrobatica Spa, Eles, Elica, Emak, Energy, Esi, Esprinet, Eviso, Fae Technology, Fiera Milano, Fope, FOS, Franchi Umberto Marmi, Giglio Group, GM Leather, GPI, Green Oleo, High Quality Food, Ikonisy, Intercos, Intred, ISCC Fintech, Lemon Sistemi, Lventure Group, Maps Group, Mare Group, Masi Agricola, Matica Fintec, Misitano & Stracuzzi, Neodecortech, Notorious Pictures, Olidata, Osai Automation System, Racing Force Group, Redfish Long Term Capital, Relatech, Reti, Sciuiker Frames, SG Company, Solid World Group, Spindox Digital Soul, Talea, Tamburi, Tesmec, Tinexta, TMP Group, Tps Group, Trendevic, Ulisse Biomed, Xenia Hôtellerie Solution Spa Società Benefit, Wit, Zest.

Intermonte SIM SpA holds net long or short positions in excess of 0.5% of the overall share capital in the following issuers:

Emittente	%	Long/Short
-----------	---	------------

© Copyright 2025 by Intermonte SIM - All rights reserved

It is a violation of national and international copyright laws to reproduce all or part of this publication by email, xerography, facsimile or any other means. The Copyright laws impose heavy liability for such infringement. The Reports of Intermonte SIM are provided to its clients only. If you are not a client of Intermonte SIM and receive emailed, faxed or copied versions of the reports from a source other than Intermonte SIM you are violating the Copyright Laws. This document is not for attribution in any publication, and you should not disseminate, distribute or copy this e-mail without the explicit written consent of Intermonte SIM.

INTERMONTE will take legal action against anybody transmitting/publishing its Research products without its express authorization.

INTERMONTE Sim strongly believes its research product on Italian equities is a value added product and deserves to be adequately paid.

Intermonte Sim sales representatives can be contacted to discuss terms and conditions to be supplied the INTERMONTE research product.

INTERMONTE SIM is MIFID compliant - for our Best Execution Policy please check our Website [MIFID](#)

Further information is available